159 related articles for article (PubMed ID: 16396772)
1. Pegfilgrastim administered in a single fixed dose is effective in inducing neutrophil count recovery after paclitaxel and topotecan chemotherapy in patients with relapsed aggressive non-Hodgkin's lymphoma.
Pro B; Fayad L; McLaughlin P; Romaguera J; Hagemeister FB; Rodriguez MA; Goy A; Loyer E; Younes A
Leuk Lymphoma; 2006 Mar; 47(3):481-5. PubMed ID: 16396772
[TBL] [Abstract][Full Text] [Related]
2. Paclitaxel plus topotecan treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma.
Younes A; Preti HA; Hagemeister FB; McLaughlin P; Romaguera JE; Rodriguez MA; Samuels BI; Palmer JL; Cabanillas F
Ann Oncol; 2001 Jul; 12(7):923-7. PubMed ID: 11521796
[TBL] [Abstract][Full Text] [Related]
3. Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma.
Vose JM; Crump M; Lazarus H; Emmanouilides C; Schenkein D; Moore J; Frankel S; Flinn I; Lovelace W; Hackett J; Liang BC
J Clin Oncol; 2003 Feb; 21(3):514-9. PubMed ID: 12560443
[TBL] [Abstract][Full Text] [Related]
4. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy.
Green MD; Koelbl H; Baselga J; Galid A; Guillem V; Gascon P; Siena S; Lalisang RI; Samonigg H; Clemens MR; Zani V; Liang BC; Renwick J; Piccart MJ;
Ann Oncol; 2003 Jan; 14(1):29-35. PubMed ID: 12488289
[TBL] [Abstract][Full Text] [Related]
5. Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer.
Holmes FA; Jones SE; O'Shaughnessy J; Vukelja S; George T; Savin M; Richards D; Glaspy J; Meza L; Cohen G; Dhami M; Budman DR; Hackett J; Brassard M; Yang BB; Liang BC
Ann Oncol; 2002 Jun; 13(6):903-9. PubMed ID: 12123336
[TBL] [Abstract][Full Text] [Related]
6. Open-label, randomized study of pegfilgrastim vs. daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin's lymphoma.
Grigg A; Solal-Celigny P; Hoskin P; Taylor K; McMillan A; Forstpointner R; Bacon P; Renwick J; Hiddemann W;
Leuk Lymphoma; 2003 Sep; 44(9):1503-8. PubMed ID: 14565651
[TBL] [Abstract][Full Text] [Related]
7. Fixed-dose pegfilgrastim is safe and allows neutrophil recovery in patients with non-Hodgkin's lymphoma.
George S; Yunus F; Case D; Yang BB; Hackett J; Shogan JE; Meza LA; Neumann TA; Liang BC
Leuk Lymphoma; 2003 Oct; 44(10):1691-6. PubMed ID: 14692520
[TBL] [Abstract][Full Text] [Related]
8. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer.
Holmes FA; O'Shaughnessy JA; Vukelja S; Jones SE; Shogan J; Savin M; Glaspy J; Moore M; Meza L; Wiznitzer I; Neumann TA; Hill LR; Liang BC
J Clin Oncol; 2002 Feb; 20(3):727-31. PubMed ID: 11821454
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of pegfilgrastim compared to granulocyte colony stimulating factor (G-CSF) supporting a dose-intensive, rapidly cycling anti-metabolite containing chemotherapy regimen (Hyper-CVAD) for lymphoid malignancy.
Lane SW; Crawford J; Kenealy M; Cull G; Seymour JF; Prince HM; Marlton P; Gill D; Mollee PN
Leuk Lymphoma; 2006 Sep; 47(9):1813-7. PubMed ID: 17064993
[TBL] [Abstract][Full Text] [Related]
10. Observational study of the prevalence of febrile neutropenia in patients who received filgrastim or pegfilgrastim associated with 3-4 week chemotherapy regimens in community oncology practices.
Morrison VA; Wong M; Hershman D; Campos LT; Ding B; Malin J
J Manag Care Pharm; 2007 May; 13(4):337-48. PubMed ID: 17506600
[TBL] [Abstract][Full Text] [Related]
11. Pegfilgrastim.
Curran MP; Goa KL
Drugs; 2002; 62(8):1207-13; discussion 1214-5. PubMed ID: 12010086
[TBL] [Abstract][Full Text] [Related]
12. Paclitaxel plus high-dose cyclophosphamide with G-CSF support in patients with relapsed and refractory aggressive non-Hodgkin's lymphoma.
Younes A; Romaguera J; Mesina O; Hagemeister F; Sarris AH; Rodriguez MA; McLaughlin P; Preti HA; Bachier C; Cabanillas F
Br J Haematol; 1998 Dec; 103(3):678-83. PubMed ID: 9858216
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of chemotherapy-induced neutropenia pegylated recombinant human granulocyte colony-stimulating factor: a multi-center randomized controlled phase II clinical study].
Shi YK; He XH; Yang S; Wang HQ; Jiang ZF; Zhu YZ; Ke XY; Zhang Y; Liu YP; Zhang WJ; Wang Z; Shi QZ; Xie XD; Zhang HL; Wang JJ; Luo DY; Zheng QS; Sun RY
Zhonghua Yi Xue Za Zhi; 2006 Dec; 86(48):3414-9. PubMed ID: 17313855
[TBL] [Abstract][Full Text] [Related]
14. Pegfilgrastim to support CHOP-14 in elderly patients with non-Hodgkin's lymphoma.
Wolf M; Bentley M; Marlton P; Horvath N; Lewis ID; Spencer A; Herrmann R; Arthur C; Durrant S; van Kerkhoven M; MacMillan J; Mrongovius R
Leuk Lymphoma; 2006 Nov; 47(11):2344-50. PubMed ID: 17107908
[TBL] [Abstract][Full Text] [Related]
15. Pegfilgrastim: using pegylation technology to improve neutropenia support in cancer patients.
Molineux G
Anticancer Drugs; 2003 Apr; 14(4):259-64. PubMed ID: 12679729
[TBL] [Abstract][Full Text] [Related]
16. A Randomized Multicenter Phase III Study of Single Administration of Mecapegfilgrastim (HHPG-19K), a Pegfilgrastim Biosimilar, for Prophylaxis of Chemotherapy-Induced Neutropenia in Patients With Advanced Non-Small-Cell Lung Cancer (NSCLC).
Zhou C; Huang Y; Wang D; An C; Zhou F; Li Y; Chen G; Wu C; He J; Wu G; Song X; Gao J; Liu W; Li B; Shi J; Huang C; Yu J; Feng J; Yue H; Shi M; Xia J
Clin Lung Cancer; 2016 Mar; 17(2):119-27. PubMed ID: 26781346
[TBL] [Abstract][Full Text] [Related]
17. Bone pain associated with once-per-cycle pegfilgrastim is similar to daily filgrastim in patients with breast cancer.
Kubista E; Glaspy J; Holmes FA; Green MD; Hackett J; Neumann T;
Clin Breast Cancer; 2003 Feb; 3(6):391-8. PubMed ID: 12636878
[TBL] [Abstract][Full Text] [Related]
18. Once-per-cycle pegfilgrastim (Neulasta) for the management of chemotherapy-induced neutropenia.
Crawford J
Semin Oncol; 2003 Aug; 30(4 Suppl 13):24-30. PubMed ID: 14508717
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and pharmacodynamics of pegfilgrastim.
Yang BB; Kido A
Clin Pharmacokinet; 2011 May; 50(5):295-306. PubMed ID: 21456630
[TBL] [Abstract][Full Text] [Related]
20. A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial.
Sierra J; Szer J; Kassis J; Herrmann R; Lazzarino M; Thomas X; Noga SJ; Baker N; Dansey R; Bosi A
BMC Cancer; 2008 Jul; 8():195. PubMed ID: 18616811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
